Mortality reduction in poor countries: exploring the association with health system resources and economic growth
ForfatterAmundrød, Eli Wik
Population health (measured in terms of life expectancy and under-five mor-tality rate) has improved under the era of the Millennium Development Goals. The aim of the thesis was to examine the association between population health and health care resources in poor countries, to better understand the situation and how to improve it. I have done an ecological analysis of aggregate data. The sample consisted of 91 low- and lower-middle-income countries. Changes in life expectancy and in under-five mortality rate from 1995 to 2009 were used as dependent variables. Included as independent variables were gross national income (GNI) per capita, total health expenditures (THE) as percentage of gross domestic product (GDP), governmental expenditures as percentage of THE, external resources as percentage of THE, separate densities of physicians and nurses, and measles vaccination coverage. The predictors of life expectancy and child mortality rate were in a large degree different. Total health expenditure (% of GDP) and external resources (% of total health expenditure) stood out as the strongest predictors. Large increase in THE as percentage of GDP and/or large increase in the percentage of THE originating from external resources, independent of the level in 1995, was considered as the most important of the predictors of improved population health. Keywords: life expectancy, under-five mortality rate, health care resources, GNI per capita
ForlagUniversitetet i Tromsø
University of Tromsø
Følgende lisensfil er knyttet til denne innførselen:
Viser innførsler relatert til tittel, forfatter og emneord.
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis Norum, Jan; Antonsen, Margaret Aarag; Tollåli, Geir; Al-Shibli, Khalid; Andersen, Gry; Svanqvist, Kristin-Helene; Helbekkmo, Nina (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-07-29)1 Norum J, et al . ESMO Open 2017; 2 :e000222. doi:10.1136/esmoopen-2017-000222 Open Access Abstr A ct Background P embrolizumab is a new drug approved in several countries for second-line therapy in non-small cell lung cancer (NSCLC) being programmed cell death ligand (PD-L1) positive. This drug has a high cost, and the cost- effectiveness ratio has been debated. Patients ...
The Use of eHealth and Provider-Based Health Services by Patients with Diabetes Mellitus: Protocol for a Cross-Sectional Study Hansen, Anne Helen; Bradway, Meghan; Brož, Jan; Claudi, Tor; Henriksen, Øystein; Wangberg, Silje C; Årsand, Eirik (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-10-31)<b>Background:</b> The prevalence of diabetes and the use of electronic health (eHealth) resources are increasing. People with diabetes need frequent monitoring and follow-up of health parameters, and eHealth services can be of great significance in this regard. However, little is known about the extent to which different kinds of eHealth tools are used, and how the use of eHealth is associated ...
Cochrane Collaboration Systematic Reviews may be based on trials not approved by a research ethics committee Jokstad, Asbjørn (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-10-27)Systematic reviews (SR) may potentially contain reports of primary trials with ethical problems. The Cochrane Collaboration SRs are considered as the highest standard in evidence-based health care resources. All SRs completed during the last 5 years (2013–2017) under the management of the Oral Health Group of the Cochrane Collaboration were identified. All primary trials included in the Oral Health ...